Medical Science Liaison Team Size and MSL Deployment Best Practices

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from "Preparing Medical Science Liaison Teams for a Changing Environment: Team Size and Deployment"

STUDY OVERVIEW

Medical Science Liaison (MSL) teams face a rapidly changing healthcare environment that requires organizations to have their MSL teams appropriately sized and deployed. Best Practices, LLC conducted this research to identify the drivers of MSL team size and explore factors affecting deployment. Insights and metrics in the study will help companies field a more efficient and effective medical field team.

KEY TOPICS

Medical Liaisons: Size Of Medical Science Liaison Teams
Medical Liaisons: Effective Operations Of Medical Science Liaison Teams

SAMPLE KEY METRICS

Regional demographics of participants
Title of respondents
Geographic span of responsibility of medical affairs at participating companies
Product scope of MSLs
Factors to determine team size
Internal stakeholder needs
Deployment of medical liaisons into the field in mature and emerging markets
Factors causing increase in the number of medical science liaisons
Factors causing decrease in the number of medical science liaisons

SAMPLE KEY FINDING

Determining Medical Science Liaison Teams’ Size: Mature Markets and Emerging Markets companies employ different strategies when determining the size of Medical Science Liaisons. Mature markets companies use company or product related factors such as “Corporate Commitment to a Franchise” or “Product Life Cycle” more often than Emerging Markets companies. Emerging Markets companies typically use an external factor, “Number of Thought Leaders,” to determine Medical Science Liaison teams’ size.

METHODOLOGY

This study engaged executives from 32 leading healthcare companies. Segmentation analysis was key to examining trends and effective practices.� Twenty three participants make up the Mature Markets Segment, while the Emerging Markets Segment consists of seven participants from Brazil, India and other Asia markets. This report includes Mature and Emerging Markets segments’ analysis.

Industries Profiled:
Biotech; Health Care; Pharmaceutical; Biopharmaceutical; Clinical Research; Laboratories; Chemical; Medical Device

Companies Profiled:
Acorda Therapeutics; United Therapeutics; Sanofi; Upsher-Smith; Kadmon Pharmaceuticals; Shire; Crescendo Bioscience; Teva Pharmaceutical Industries Ltd; Lilly; Baxter BioScience; Merck; Cubist Pharmaceuticals; Pierre Fabre Medicament; Amgen; ProStrakan; Dr Reddy's Laboratories; Biocon; Genentech; Astellas; Ironwood; Biogen Idec; AstraZeneca; Covidien

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Preparing Medical Science Liaison Teams for a Changing Environment: Team Size and Deployment

ID: 5314

Features:

Pages/Slides: 26

Published: Pre-2018

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61F85C774BFF88F5765257D0A003A1B7F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-preparing-medical-science-liaison-teams-for-a-changing-environment-team-size-and-deployment?opendocument
18
19opendocument
203.235.188.113
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB